Warfarin manufacturers and suppliers in india

Warfarin

Properties

Melting point:: 162-164 °C(lit.)

Boiling point:: 356°C

Density: 1.1411 (rough estimate)

vapor pressure: 0.09 at 22 °C (NIOSH, 1997)

refractive index: 1.4434 (estimate)

Flash point:: 2℃

storage temp.: 2-8°C

solubility: Soluble in benzene, 1,4-dioxane (Weast, 1986), and acetone (Sax and Lewis, 1987). Moderately soluble in methanol, ethanol, isopropanol, and some oils (Windholz et al., 1983). Also soluble in toluene.

form: Crystalline

pka: pKa 4.90±0.01(H2O t = 25±0.5 I = 0.15 (KCl))(Approximate)

color: Colorless

Odor: odorless

Water Solubility: Practically insoluble

Merck: 13,10097

BRN: 8868198

Exposure limits: NIOSH REL: TWA 0.1 mg/m3, IDLH 100 mg/m3; OSHA PEL: 0.1 mg/m3; ACGIH TLV: TWA 0.1 mg/m3.

LogP: 2.600

Safety Information

Symbol(GHS): GHS06,GHS08,GHS09

Signal word: Danger

Hazard statements: H300+H310+H330-H360D-H372-H411

Precautionary statements: P202-P264-P273-P280-P302+P352+P310-P304+P340+P310

Hazard Codes: T,T+,Xn,F

Risk Statements: 61-48/25-52/53-28-21-36-20/21/22-11

Safety Statements: 53-45-61-52-36/37-28-26-16

RIDADR: UN 2811 6.1/PG 1

OEB: D

OEL: TWA: 0.1 mg/m3

WGK Germany: 3

RTECS: GN4550000

HazardClass: 6.1(a)

PackingGroup: I

HS Code: 29322090

Toxicity: EC50 (24-hour) for Daphnia magna 88.8 mg/L (Lilius et al., 1995); acute oral LD50 for rats 186 mg/kg (Hartley and Kidd, 1987), 3 mg/kg (RTECS, 1985)

IDLA: 100 mg/m3

Use

Warfarin is tasteless and colorless. It is a widely used as anticoagulant (which stops the blood clotting) in the treatment and prevention of thrombosis, in the treatment for chronic atrial fibrillation, mechanical valves, pulmonary embolism, and dilated cardiomyopathy. Warfarin is metabolized primarily via oxidation in the liver by CYP2C9, and exerts its anticoagulant effect by inhibiting the protein vitamin K epoxide reductase complex, subunit 1 (VKORC1). Warfarin therapy can be associated with significant bleeding complications. Achieving a safe therapeutic response can be difficult because of warfarins narrow therapeutic index and great individual variability in the dose required, which is mostly a consequence of individual genetic variants: it is influenced by ageing, co-prescribed drugs, diet, alcohol consumption, and comorbid conditions. To maintain a therapeutic level of anti-thrombosis and to minimize the risk of bleeding complications, warfarin therapy requires intensive monitoring via the INR to guide its dosing. It is also used as the first generation of anticoagulant rodenticides.